470 related articles for article (PubMed ID: 20931366)
21. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
Nagstrup AH
Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
[TBL] [Abstract][Full Text] [Related]
22. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells.
Guenoun JM; Baudouin C; Rat P; Pauly A; Warnet JM; Brignole-Baudouin F
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4594-9. PubMed ID: 16303954
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system.
Yee RW; Norcom EG; Zhao XC
Adv Ther; 2006; 23(4):511-9. PubMed ID: 17050493
[TBL] [Abstract][Full Text] [Related]
24. The effects of combination glaucoma medications on ocular surface epithelial cells.
Ammar DA; Kahook MY
Adv Ther; 2009 Oct; 26(10):970-5. PubMed ID: 19921496
[TBL] [Abstract][Full Text] [Related]
25. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
26. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride.
McCarey B; Edelhauser H
J Ocul Pharmacol Ther; 2007 Oct; 23(5):445-51. PubMed ID: 17941807
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of topical travoprost with sofzia preservative for Japanese glaucoma patients.
Kanamoto T; Kiuchi Y; Suehiro T; Nakano T; Nakano Y; Hirota A; Miyata A
Hiroshima J Med Sci; 2010 Dec; 59(4):71-5. PubMed ID: 21361083
[TBL] [Abstract][Full Text] [Related]
28. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
29. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride.
Liang H; Baudouin C; Pauly A; Brignole-Baudouin F
Br J Ophthalmol; 2008 Sep; 92(9):1275-82. PubMed ID: 18723745
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system.
Ryan G; Fain JM; Lovelace C; Gelotte KM
BMC Ophthalmol; 2011 Apr; 11():8. PubMed ID: 21510881
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models.
Liang H; Baudouin C; Daull P; Garrigue JS; Buggage R; Brignole-Baudouin F
Cornea; 2012 Nov; 31(11):1319-29. PubMed ID: 22929154
[TBL] [Abstract][Full Text] [Related]
32. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride.
Whitson JT; Cavanagh HD; Lakshman N; Petroll WM
Adv Ther; 2006; 23(5):663-71. PubMed ID: 17142200
[TBL] [Abstract][Full Text] [Related]
33. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
34. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
35. Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells.
Hedengran A; Freiberg J; May Hansen P; Boix-Lemonche G; Utheim TP; Dartt DA; Petrovski G; Heegaard S; Kolko M
J Optom; 2024; 17(1):100481. PubMed ID: 37788596
[TBL] [Abstract][Full Text] [Related]
36. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
37. Acute effects of glaucoma medications and benzalkonium chloride on pre-adipocyte proliferation and adipocyte cytotoxicity in vitro.
Seibold LK; Ammar DA; Kahook MY
Curr Eye Res; 2013 Jan; 38(1):70-4. PubMed ID: 23078159
[TBL] [Abstract][Full Text] [Related]
38. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
[TBL] [Abstract][Full Text] [Related]
39. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
[TBL] [Abstract][Full Text] [Related]
40. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost.
Pellinen P; Lokkila J
Ophthalmic Res; 2009; 41(2):118-22. PubMed ID: 19147999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
